Previous 10 | Next 10 |
First time an antigen presenting cell (APC) activator has shown an Overall Survival (OS) benefit in a randomised setting in metastatic breast cancer patients known to be insensitive to immune checkpoint inhibitor therapy Promising and improving overall trend in OS in total population ...
Immutep ([[IMMP]] -5.9%) has expanded its collaboration trial to include an additional 74 patients with 1st line non-small cell lung cancer ((NSCLC)) (Part A), the most advanced part of its ongoing Phase 2 TACTI-002 trial evaluating eftilagimod alpha (efti/IMP321”) with Merck...
Gainers: Medigus (MDGS) +30%, Aptevo Therapeutics (APVO) +29%, Corcept Therapeutics (CORT) +23%, Opiant Pharmaceuticals (OPNT) +15%, Aquestive Therapeutics (AQST) +11%.Losers: MeiraGTx Holdings (MGTX) -11%, Kintara Therapeutics (KTRA) -10%,...
Additional 74 patients with 1 st line non-small cell lung cancer (NSCLC) to be enrolled, more than tripling patient numbers in this indication Follows encouraging interim data from 1 st line NSCLC patients First Patient is expected to be enrolled in the expanded trial by t...
Sydney, Australia, Nov. 19, 2020 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) : Australian biotechnology company Immutep Limited (“ Immutep “ or the “ Company “), which is listed on NASDAQ and the Australian Securities Exchange...
Sydney, Australia, Nov. 09, 2020 (GLOBE NEWSWIRE) -- ASX/Media Release Overall Response Rates (ORR) in 1 st line NSCLC and 2 nd line HNSCC continue to be very favourable 5 patients with a Complete Response (disappearance of all lesions): 2 patients in 1 st line N...
Immutep (IMMP) announces the grant of patent no. 2015229103 entitled “Antibody molecules to LAG-3 and uses thereof” by the Australian Patent Office. LAG525 is a humanised form of Immutep’s IMP701 antibody which is out-licensed to Novartis AG. The patent is co-owned by Nov...
Sydney, Australia, Nov. 09, 2020 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or the “Company”) announces the grant of patent no. 2015229103 entitled “Antibody molecules to LAG-3 and uses thereof” by the Australian Pat...
SYDNEY, Australia, Nov. 02, 2020 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, is pleased to announce more mature in...
SYDNEY, Australia, Oct. 29, 2020 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune disease, is pleased to announce that it has entered into a Licence and Collaboration Agreement with ...
News, Short Squeeze, Breakout and More Instantly...
Media Release Study expected to enrol first participants during Q3 CY2024 SYDNEY, AUSTRALIA, July 17, 2024 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing no...
2024-07-12 10:45:04 ET QuantumScape Corp (QS) QS is trading UP for the last 5 days, and it at trading at $7.84 with volume of 22,322,158 and a one day change of $0.78 (10.98%). QuantumScape Corp has a 52-week low of 4.67 and a 52-week high of $13.86. The business's 50-day moving ave...
Media Release Efti in combination with KEYTRUDA® (pembrolizumab) achieved a 35.5% response rate in evaluable patients (N=31), according to RECIST 1.1, among the highest recorded for a treatment approach not containing chemotherapy in patients with CPS <1 High complete response...